Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Open, Phase IV, Parallel Group Multicentre Study to Evaluate a Change of Management in Gastroesophageal Reflux Disease (GERD) Patients by Treatment With Esomeprazole 40 mg or Any Other Proton Pump Inhibitor (PPI), After Initial Treatment Failure, in Ordinary Clinical Practice During 4 Weeks.

NCT00272701 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00272701
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00272701 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Open, Phase IV, Parallel Group Multicentre Study to Evaluate a Change of Management in Gastroesophageal Reflux Disease (GERD) Patients by Treatment With Esomeprazole 40 mg or Any Other Proton Pump Inhibitor (PPI), After Initial Treatment Failure, in Ordinary Clinical Practice During 4 Weeks.
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
December 31, 2005
Completion date
February 28, 2007
Enrollment
450 (estimated)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

gastroesophageal reflux disease